• 01Company
    Company
    Vision and Values
    Citizenship
    Leadership Team
    Board of Directors
    Our Locations
  • 02Products & Services
    Products
    R&D
    Generics
    Export Oncology
    Facilities
    Contract Research
  • 03Investors
    Investors
    Corporate Governance
    Monthly Sales
    Quarterly Results
    Shareholders Services
    Financial Calendar
  • 04Newsroom
Contact Us
Language
Languages
  • English
  • Chinese
  • Alvogen Korea
Contact Us
Language
Languages
  • English
  • Chinese
  • Alvogen Korea
Newsroom
Company
Vision and Values
Citizenship
Leadership Team
Board of Directors
Our Locations
Products
R&D
Generics
Export Oncology
Facilities
Contract Research
Investors
Corporate Governance
Monthly Sales
Quarterly Results
Shareholders Services
Financial Calendar
Skip Navigation
Newsroom

Featured News

  • Investors
    16 May 2023

    Lotus Reports Strong 1Q 2023 Results with EPS of NT$4.58

  • Investors
    10 May 2023

    Monthly sales report for April 2023

  • Investors
    12 April 2023

    Monthly sales report for March 2023

  • Business
    27 March 2023

    Lotus Announces MFDS Approval for GRALISE® SR, Once-Daily Tablets for Post-Herpetic Neuralgia

  • Investors
    10 March 2023

    Lotus’ revenues grow by 16% and profit doubles year over year

  • Investors
    10 March 2023

    Lotus hosts fourth quarter 2022 results investor conference

  • Investors
    10 March 2023

    Monthly sales report for February 2023

  • Business
    01 March 2023

    Lotus is the First to Launch Vinorelbine Soft Gel Capsules in Vietnam

  • Charity
    15 February 2023

    Lotus Donates One Million Dollars to Support Turkey and Syria Earthquake Victims

  • Company
  • Products & Services
  • Investors
  • Newsroom
  • Contact Us
    • Privacy Policy
    • Terms of Use

    © 2021 Lotus. All Rights Reserved